Skip to main content Accessibility help
×
Home
  • Cited by 1
  • Print publication year: 2011
  • Online publication date: August 2011

5 - Wilson disease

Related content

Powered by UNSILO

References

1. Ferenci P, Caca K, Loudianos G et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003; 23: 139–42.
2. El-Youssef M. Wilson disease. Mayo Clin Proc 2003; 78: 1126–36.
3. Prashanth LK, Taly AB, Sinha S, Arunodaya GR, Swamy HS. Wilson’s disease: diagnostic errors and clinical implications. J Neurol Neurosurg Psychiatry 2004; 75: 907–9.
4. Brewer GJ, Askari FK. Wilson’s disease: clinical management and therapy. J Hepatol 2005; 42(Suppl 1): S13–21.
5. Das SK, Ray K. Wilson’s disease: an update. Nat Clin Pract Neurol 2006; 2: 482–93.
6. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson’s disease. Lancet 2007; 369: 397–408.
7. Pfeiffer RF. Wilson’s disease. Semin Neurol 2007; 27: 123–32.
8. Taly AB, Meenakshi-Sundaram S, Sinha S, Swamy HS, Arunodaya GR. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007; 86: 112–21.
9. Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut 2007; 56: 115–20.
10. Roberts EA, Schilsky ML, American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47: 2089–111.
11. Scheinberg IH, Sternlieb I. Wilson’s disease. Major Probl Intern Med 1984; 23: 1–24.
12. Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34: 295–509.
13. Walshe JM. History of Wilson’s disease: 1912 to 2000. Mov Disord 2006; 21: 142–7.
14. Tanzi RE, Petrukhin K, Chernov I et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5: 344–50.
15. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5: 327–37.
16. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 1993; 197: 271–7.
17. Petrukhin K, Fischer SG, Pirastu M et al. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat Genet 1993; 5: 338–43.
18. Cox DW, Prat L, Walshe JM, Heathcote J, Gaffney D. Twenty-four novel mutations in Wilson disease patients of predominantly European ancestry. Hum Mutat 2005; 26: 280.
19. Gromadzka G, Schmidt HH, Genschel J et al. Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson’s disease. Clin Genet 2005; 68: 524–32.
20. Schiefermeier M, Kollegger H, Madl C et al. The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson’s disease. Brain 2000; 123(Pt 3): 585–90.
21. Mufti AR, Burstein E, Csomos RA et al. XIAP Is a copper binding protein deregulated in Wilson’s disease and other copper toxicosis disorders. Mol Cell 2006; 17(21): 775–85.
22. Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology 2005; 41: 668–70.
23. Schilsky ML, Fink S. Inherited metabolic liver disease. Curr Opin Gastroenterol 2006; 22: 215–22.
24. Poston KL, Frucht SJ. Movement disorder emergencies. J Neurol 2008; 255(Suppl 4): 2–13.
25. Svetel M, Kozic D, Stefanova E, Semnic R, Dragasevic N, Kostic VS. Dystonia in Wilson’s disease. Mov Disord 2001; 16: 719–23.
26. Parker N. Hereditary whispering dysphonia. J Neurol Neurosurg Psychiatry 1985; 48: 218–24.
27. Cartwright GE. Diagnosis of treatable Wilson’s disease. N Engl J Med 1978; 298: 1347–50.
28. Crone NE, Jinnah HA, Reich SG. Wilson’s disease presenting with an unusual cough. Mov Disord 2005; 20: 891–3.
29. Barbosa ER, Silveira-Moriyama L, Machado AC, Bacheschi LA, Rosemberg S, Scaff M. Wilson’s disease with myoclonus and white matter lesions. Parkinsonism Relat Disord 2007; 13: 185–8.
30. Papapetropoulos S, Singer C. Painless legs moving toes in a patient with Wilson’s disease. Mov Disord 2006; 21: 579–80.
31. Kumar TS, Moses PD. Isolated tongue involvement – an unusual presentation of Wilson’s disease. J Postgrad Med 2005; 51: 337.
32. Dening TR, Berrios GE, Walshe JM. Wilson’s disease and epilepsy. Brain 1988; 111(Pt 5): 1139–55.
33. Meenakshi-Sundaram S, Taly AB, Kamath V, Arunodaya GR, Rao S, Swamy HS. Autonomic dysfunction in Wilson’s disease – a clinical and electrophysiological study. Clin Auton Res 2002; 12: 185–9.
34. Jung KH, Ahn TB, Jeon BS. Wilson disease with an initial manifestation of polyneuropathy. Arch Neurol 2005; 62: 1628–31.
35. Mueller A, Reuner U, Landis B, Kitzler H, Reichmann H, Hummel T. Extrapyramidal symptoms in Wilson’s disease are associated with olfactory dysfunction. Mov Disord 2006; 21: 1311–6.
36. Seniow J, Bak T, Gajda J, Poniatowska R, Czlonkowska A. Cognitive functioning in neurologically symptomatic and asymptomatic forms of Wilson’s disease. Mov Disord 2002; 17: 1077–83.
37. Dening TR. The neuropsychiatry of Wilson’s disease: a review. Int J Psychiatry Med 1991; 21: 135–48.
38. Lin JJ, Lin KL, Wang HS, Wong MC. Psychological presentations without hepatic involvement in Wilson disease. Pediatr Neurol 2006; 35: 284–6.
39. Wiebers DO, Hollenhorst RW, Goldstein NP. The ophthalmologic manifestations of Wilson’s disease. Mayo Clin Proc 1977; 52: 409–16.
40. Steindl P, Ferenci P, Dienes HP et al. Wilson’s disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997; 113: 212–8.
41. Demirkiran M, Jankovic J, Lewis RA, Cox DW. Neurologic presentation of Wilson disease without Kayser–Fleischer rings. Neurology 1996; 46: 1040–3.
42. Innes JR, Strachan IM, Triger DR. Unilateral Kayser–Fleischer ring. Br J Ophthalmol 1986; 70: 469–70.
43. Cauza E, Maier-Dobersberger T, Polli C, Kaserer K, Kramer L, Ferenci P. Screening for Wilson’s disease in patients with liver diseases by serum ceruloplasmin. J Hepatol 1997; 27: 358–62.
44. McMillin GA, Travis JJ, Hunt JW. Direct measurement of free copper in serum or plasma ultrafiltrate. Am J Clin Pathol 2009; 131: 160–5.
45. Martins da Costa C, Baldwin D, Portmann B, Lolin Y, Mowat AP, Mieli-Vergani G. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson’s disease. Hepatology 1992; 15: 609–15.
46. Ferenci P, Steindl-Munda P, Vogel W et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson’s disease. Clin Gastroenterol Hepatol 2005; 3: 811–8.
47. Williams FJ, Walshe JM. Wilson’s disease. An analysis of the cranial computerized tomographic appearances found in 60 patients and the changes in response to treatment with chelating agents. Brain 1981; 104(Pt 4): 735–52.
48. Sinha S, Taly AB, Ravishankar S et al. Wilson’s disease: cranial MRI observations and clinical correlation. Neuroradiology 2006; 48: 613–21.
49. Hedera P, Brewer GJ, Fink JK. White matter changes in Wilson disease. Arch Neurol 2002; 59: 866–7.
50. Yoshii F, Takahashi W, Shinohara Y. A Wilson’s disease patient with prominent cerebral white matter lesions: five-year follow-up by MRI. Eur Neurol 1996; 36: 392–3.
51. Sinha S, Taly AB, Prashanth LK, Ravishankar S, Arunodaya GR, Vasudev MK. Sequential MRI changes in Wilson’s disease with de-coppering therapy: a study of 50 patients. Br J Radiol 2007; 80: 744–9.
52. Giagheddu M, Tamburini G, Piga M et al. Comparison of MRI, EEG, EPs and ECD-SPECT in Wilson’s disease. Acta Neurol Scand 2001; 103: 71–81.
53. Jacobs DA, Markowitz CE, Liebeskind DS, Galetta SL. The “double panda sign” in Wilson’s disease. Neurology 2003; 61: 969.
54. Liebeskind DS, Wong S, Hamilton RH. Faces of the giant panda and her cub: MRI correlates of Wilson’s disease. J Neurol Neurosurg Psychiatry 2003; 74: 682.
55. Sener RN. The claustrum on MRI: normal anatomy, and the bright claustrum as a new sign in Wilson’s disease. Pediatr Radiol 1993; 23: 594–6.
56. Sener RN. Diffusion MR imaging changes associated with Wilson disease. AJNR Am J Neuroradiol 2003; 24: 965–7.
57. Van Den Heuvel AG, Van der Grond J, Van Rooij LG, Van Wassenaer-van Hall HN, Hoogenraad TU, Mali WP. Differentiation between portal-systemic encephalopathy and neurodegenerative disorders in patients with Wilson disease: H-1 MR spectroscopy. Radiology 1997; 203: 539–43.
58. Lucato LT, Otaduy MC, Barbosa ER et al. Proton MR spectroscopy in Wilson disease: analysis of 36 cases. AJNR Am J Neuroradiol 2005; 26: 1066–71.
59. Tarnacka B, Szeszkowski W, Golebiowski M, Czlonkowska A. MR spectroscopy in monitoring the treatment of Wilson’s disease patients. Mov Disord 2008; 23: 1560–6.
60. Jeon B, Kim JM, Jeong JM et al. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson’s disease. J Neurol Neurosurg Psychiatry 1998; 65: 60–4.
61. Snow BJ, Bhatt M, Martin WR, Li D, Calne DB. The nigrostriatal dopaminergic pathway in Wilson’s disease studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991; 54: 12–7.
62. Walter U, Krolikowski K, Tarnacka B, Benecke R, Czlonkowska A, Dressler D. Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease. Neurology 2005; 64: 1726–32.
63. Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ. Treatment of Wilson’s disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2003; 142: 385–90.
64. Brewer GJ, Askari F, Lorincz MT et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006; 63: 521–7.
65. Walshe JM. Penicillamine: the treatment of first choice for patients with Wilson’s disease. Mov Disord 1999; 14: 545–50.
66. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Arch Neurol 1987; 44(5): 490–3.
67. Brewer GJ. Penicillamine should not be used as initial therapy in Wilson’s disease. Mov Disord 1999; 14: 551–4.
68. LeWitt PA. Penicillamine as a controversial treatment for Wilson’s disease. Mov Disord 1999; 14: 555–6.
69. Sternlieb I, Fisher M, Scheinberg IH. Penicillamine-induced skin lesions. J Rheumatol Suppl 1981; 7: 149–54.
70. Hanukoglu A, Curiel B, Berkowitz D, Levine A, Sack J, Lorberboym M. Hypothyroidism and dyshormonogenesis induced by d-penicillamine in children with Wilson’s disease and healthy infants born to a mother with Wilson’s disease. J Pediatr 2008; 153: 864–6.
71. Shiono Y, Wakusawa S, Hayashi H et al. Iron accumulation in the liver of male patients with Wilson’s disease. Am J Gastroenterol 2001; 96: 3147–51.
72. Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson’s disease. Ann Intern Med 1983; 99: 314–9.
73. Schilsky ML, Blank RR, Czaja MJ et al. Hepatocellular copper toxicity and its attenuation by zinc. J Clin Invest 1989; 84: 1562–8.
74. Hoogenraad TU, Van Hattum J, Van den Hamer CJ. Management of Wilson’s disease with zinc sulphate. Experience in a series of 27 patients. J Neurol Sci 1987; 77(2–3): 137–46.
75. Foubert-Samier A, Kazadi A, Rouanet M et al. Axonal sensory motor neuropathy in copper-deficient Wilson’s disease. Muscle Nerve 2009; 40: 294–6.
76. Brewer GJ, Hedera P, Kluin KJ et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003; 60: 379–85.
77. Brewer GJ, Askari F, Dick RB et al. Treatment of Wilson’s disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Translational Research: J Lab Clin Med 2009; 154: 70–7.
78. Tamura S, Sugawara Y, Kishi Y, Akamatsu N, Kaneko J, Makuuchi M. Living-related liver transplantation for Wilson’s disease. Clin Transplant 2005; 19: 483–6.
79. Schumacher G, Platz KP, Mueller AR et al. Liver transplantation in neurologic Wilson’s disease. Transplant Proc 2001; 33(1–2): 1518–9.
80. Medici V, Mirante VG, Fassati LR et al. Liver transplantation for Wilson’s disease: The burden of neurological and psychiatric disorders. Liver Transpl 2005; 11: 1056–63.
81. Schilsky ML. Wilson disease: current status and the future. Biochimie 2009; 91: 1278–81.
82. Kumar N. Copper deficiency myelopathy: human swayback. Mayo Clin Proc 2006; 81: 1371–84.